In line with earlier findings linking MKK4 inhibitionto antiproliferative effects in HCC cells in a NASH-HCC context, this model serves as a surrogate to examineboth selectivity and potential safety concerns. Here, MAP2K4 is linked to hepatocellular carcinoma.